NCT04347616 2026-03-16
NK4AML
Radboud University Medical Center
Phase 1/2 Terminated
Clinical Trials
125 trialsNCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
NCT04421560 2026-02-20
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06644183 2026-02-11
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06007937 2026-02-05
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT04467723 2026-01-28
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
University of Kansas Medical Center
Phase 1/2 Recruiting
NCT05300282 2026-01-28
FIL_A-BEGEV
Fondazione Italiana Linfomi - ETS
Phase 1/2 Recruiting
NCT06208657 2026-01-28
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer
Australian & New Zealand Children's Haematology/Oncology Group
Phase 1/2 Recruiting
NCT07288814 2025-12-17
Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06494579 2025-12-16
Lamivudine for Solid Tumors
Icahn School of Medicine at Mount Sinai
Phase 1/2 Active not recruiting
NCT06518551 2025-12-11
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT02932280 2025-12-05
Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT03233152 2025-11-21
GlitIpNi
Universitair Ziekenhuis Brussel
Phase 1/2 Active not recruiting
NCT03160079 2025-11-10
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
University of California, San Diego
Phase 1/2 Completed
NCT06090864 2025-10-20
ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07206563 2025-10-03
Penfluridol for Relapsed/Refractory Small Cell Cancers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Not yet recruiting
NCT04697940 2025-09-19
Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL
Chinese PLA General Hospital
Phase 1/2 Active not recruiting
NCT05658640 2025-09-16
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05745714 2025-09-16
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05751044 2025-09-16
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT07175415 2025-09-16
HEM-iSMART E
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Not yet recruiting
NCT05990543 2025-09-08
Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer
Korea University Anam Hospital
Phase 1/2 Active not recruiting
NCT03672721 2025-08-11
IA Carboplatin + Radiotherapy in Relapsing GBM
Université de Sherbrooke
Phase 1/2 Recruiting
NCT06838832 2025-07-30
Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT05182385 2025-07-25
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Goethe University
Phase 1/2 Active not recruiting
NCT02956382 2025-07-18
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Georgetown University
Phase 1/2 Completed
NCT06987916 2025-06-05
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1/2 Recruiting
NCT04358237 2025-06-04
LUPER
Blanco, Dr Antonio Calles MD
Phase 1/2 Completed
NCT00081874 2025-04-27
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT06721689 2025-03-26
PEEL-224
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT06855823 2025-03-04
A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Sun Yat-sen University
Phase 1/2 Recruiting
NCT02202772 2025-02-24
CGC
Columbia University
Phase 1/2 Active not recruiting
NCT06834529 2025-02-19
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
Phase 1/2 Recruiting
NCT04758533 2024-12-27
AloCELYVIR
Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Phase 1/2 Active not recruiting
NCT06735495 2024-12-16
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Recruiting
NCT06420063 2024-11-12
BAH244
Essen Biotech
Phase 1/2 Recruiting
NCT03919240 2024-10-24
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
Phase 1/2 Active not recruiting
NCT03658785 2024-08-13
Immunotherapy for the Treatment of Advanced Solid Tumor
Tongji Hospital
Phase 1/2 Recruiting
NCT06503094 2024-07-16
CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Recruiting
NCT05740449 2024-06-21
HEM-iSMART A
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Withdrawn
NCT02341014 2024-04-04
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT03056339 2024-03-25
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02282358 2024-03-08
Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
NCT03643549 2024-02-29
BORTEM-17
Haukeland University Hospital
Phase 1/2 Unknown
NCT03257722 2024-02-28
PIL
Augusta University
Phase 1/2 Terminated
NCT04092179 2024-01-24
ENAVEN-AML
University Health Network, Toronto
Phase 1/2 Terminated
NCT01545141 2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT02096042 2023-10-10
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05896046 2023-06-15
SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT01066663 2023-02-22
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Dana-Farber Cancer Institute
Phase 1/2 Completed